CoChat
Sign Up
Cited by 10Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismLipid metabolism and disorders

Cholesterol Lowering Biotechnological Strategies: From Monoclonal Antibodies to Antisense Therapies. A Pre-Clinical Perspective Review

Open access
Bellosta, S., Rossi, C., Alieva, A. S., Catapano, A. L., Corsini, A., Baragetti, A.·2023·Cardiovascular Drugs and Therapy
DOI 10.1007/s10557-021-07293-w
Open this paper in CoChat — free accountOpen PDF

Abstract

In recent years, the increase in available genetic information and a better understanding of the genetic bases of dyslipidemias has led to the identification of potential new avenues for therapies. Additionally, the development of new technologies has presented the key for developing novel therapeutic strategies targeting not only proteins (e.g., the monoclonal antibodies and vaccines) but also the transcripts (from antisense oligonucleotides (ASOs) to small interfering RNAs) or the genomic sequence (gene therapies). These pharmacological advances have led to successful therapeutic improvements, particularly in the cardiovascular arena because we are now able to treat rare, genetically driven, and previously untreatable conditions (e.g, familial hypertriglyceridemia or hyperchylomicronemia). In this review, the pre-clinical pharmacological development of the major biotechnological cholesterol lowering advances were discussed, describing facts, gaps, potential future steps forward, and therapeutic opportunities.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10557-021-07293-w

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 73

  1. Collaboration, C.T.T. (CTT) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010, 376, 1670-1681, doi:10.1016/S0140- 6736(10)61350-5. · DOI · Paper page
  2. Bhatt, D.L.; Steg, P.G.; Miller, M.; Brinton, E.A.; Jacobson, T.A.; Ketchum, S.B.; Ralph T. Doyle, J.; Juliano, R.A.; Jiao, L.; Granowitz, C.; et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. https://doi.org/10.1056/NEJMoa1812792 2018, 380, 11-22, doi:10.1056/NEJMOA1812792. · DOI
  3. Packard, C.; Chapman, M.J.; Sibartie, M.; Laufs, U.; Masana, L. Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges. Heart 2021, 107, 1369-1375, doi:10.1136/heartjnl-2020-318760. · DOI
  4. Ghetie, V.; Ward, E.S. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu. Rev. Immunol. 2000, 18, 739-766.
  5. Tabrizi, M.A.; Tseng, C.M.L.; Roskos, L.K. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov. Today 2006, 11, 81-88.
  6. Foltz, I.N.; Karow, M.; Wasserman, S.M. Evolution and emergence of therapeutic monoclonal antibodies what cardiologists need to know. Circulation 2013, 127, 2222-2230, doi:10.1161/CIRCULATIONAHA.113.002033. · DOI
  7. Guedeney, P.; Giustino, G.; Sorrentino, S.; Claessen, B.E.; Camaj, A.; Kalkman, D.N.; Vogel, B.; Sartori, S.; De Rosa, S.; Baber, U.; et al. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. Eur. Heart J. 2019, doi:10.1093/EURHEARTJ/EHZ430. · DOI · Paper page
  8. Kühnast, S.; Van Der Hoorn, J.W.A.; Pieterman, E.J.; Van Den Hoek, A.M.; Sasiela, W.J.; Gusarova, V.; Peyman, A.; Schäfer, H.L.; Schwahn, U.; Jukema, J.W.; et al. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J. Lipid Res. 2014, 55, 2103-2112, doi:10.1194/jlr.M051326. · DOI · Paper page
  9. Pouwer, M.G.; Pieterman, E.J.; Worms, N.; Keijzer, N.; Jukema, J.W.; Gromada, J.; Gusarova, V.; Princen, H.M.G. Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice. J. Lipid Res. 2020, 61, 365-375, doi:10.1194/jlr.RA119000419. · DOI · Paper page
  10. Shen, Y.; Li, H.; Zhao, L.; Li, G.; Chen, B.; Guo, Q.; Gao, B.; Wu, J.; Yang, T.; Jin, L.; et al. Increased half-life and enhanced potency of Fc-modified human PCSK9 monoclonal antibodies in primates. PLoS One 2017, 12, doi:10.1371/journal.pone.0183326. · DOI
  11. Chan, J.C.Y.; Piper, D.E.; Cao, Q.; Liu, D.; King, C.; Wang, W.; Tang, J.; Liu, Q.; Higbee, J.; Xia, Z.; et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl. Acad. Sci. 2009, 106, 9820-9825, doi:10.1073/pnas.0903849106. · DOI
  12. Qi, Z.; Hu, L.; Zhang, J.; Yang, W.; Liu, X.; Jia, D.; Yao, Z.; Chang, L.; Pan, G.; Zhong, H.; et al. PCSK9 Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36. Circulation 2020, doi:10.1161/circulationaha.120.046290. · DOI · Paper page
  13. Wu, Y.; Xu, M.J.; Cao, Z.; Yang, C.; Wang, J.; Wang, B.; Liu, J.; Wang, Y.; Xian, X.; Zhang, F.; et al. Heterozygous ldlr-deficient hamster as a model to evaluate the efficacy of PCSK9 antibody in hyperlipidemia and atherosclerosis. Int. J. Mol. Sci. 2019, 20, doi:10.3390/ijms20235936. · DOI
  14. Khoshnejad, M.; Patel, A.; Wojtak, K.; Kudchodkar, S.B.; Humeau, L.; Lyssenko, N.N.; Rader, D.J.; Muthumani, K.; Weiner, D.B. Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics. Mol. Ther. 2019, 27, 188-199, doi:10.1016/j.ymthe.2018.10.016. · DOI
  15. Desai, U.; Lee, E.C.; Chung, K.; Gao, C.; Gay, J.; Key, B.; Hansen, G.; Machajewski, D.; Platt, K.A.; Sands, A.T.; et al. Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 11766-11771, doi:10.1073/pnas.0705041104. · DOI
  16. Harada-Shiba, M.; Ali, S.; Gipe, D.A.; Gasparino, E.; Son, V.; Zhang, Y.; Pordy, R.; Catapano, A.L. A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects. Atherosclerosis 2020, 314, 33-40, doi:10.1016/j.atherosclerosis.2020.10.013. · DOI
  17. Raal, F.J.; Rosenson, R.S.; Reeskamp, L.F.; Hovingh, G.K.; Kastelein, J.J.P.; Rubba, P.; Ali, S.; Banerjee, P.; Chan, K.-C.; Gipe, D.A.; et al. Evinacumab for Homozygous Familial Hypercholesterolemia. N. Engl. J. Med. 2020, 383, 711-720, doi:10.1056/nejmoa2004215. · DOI · Paper page
  18. Gusarova, V.; Alexa, C.A.; Wang, Y.; Rafique, A.; Kim, J.H.; Buckler, D.; Mintah, I.J.; Shihanian, L.M.; Cohen, J.C.; Hobbs, H.H.; et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J. Lipid Res. 2015, 56, 1308-1317, doi:10.1194/jlr.M054890. · DOI · Paper page
  19. Lee, E.C.; Desai, U.; Gololobov, G.; Hong, S.; Feng, X.; Yu, X.C.; Gay, J.; Wilganowski, N.; Gao, C.; Du, L.L.; et al. Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL). J. Biol. Chem. 2009, 284, 13735- 13745, doi:10.1074/jbc.M807899200. · DOI
  20. Fattori, E.; Cappelletti, M.; Lo Surdo, P.; Calzetta, A.; Bendtsen, C.; Ni, Y.G.; Pandit, S.; Sitlani, A.; Mesiti, G.; Carfí, A.; et al. Immunization against proprotein convertase subtilisin-like/kexin type 9 lowers plasma LDL- cholesterol levels in mice. J. Lipid Res. 2012, 53, 1654-1661, doi:10.1194/jlr.M028340. · DOI
  21. Galabova, G.; Brunner, S.; Winsauer, G.; Juno, C.; Wanko, B.; Mairhofer, A.; Luhrs, P.; Schneeberger, A.; von Bonin, A.; Mattner, F.; et al. Peptide-based anti-PCSK9 vaccines -an approach for long-term LDLc management. PLoS One 2014, 9, e114469, doi:10.1371/journal.pone.0114469. · DOI
  22. Landlinger, C.; Pouwer, M.G.; Juno, C.; van der Hoorn, J.W.A.; Pieterman, E.J.; Jukema, J.W.; Staffler, G.; Princen, H.M.G.; Galabova, G. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. Eur Hear. J 2017, 38, 2499-2507, doi:10.1093/eurheartj/ehx260. · DOI
  23. Kawakami, R.; Nozato, Y.; Nakagami, H.; Ikeda, Y.; Shimamura, M.; Yoshida, S.; Sun, J.; Kawano, T.; Takami, Y.; Noma, T.; et al. Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/ kexin type 9 (PCSK9) epitope in mice. PLoS One 2018, 13, doi:10.1371/journal.pone.0191895. · DOI
  24. Ji, H.; Wu, G.; Li, Y.; Wang, K.; Xue, X.; You, S.; Wu, S.; Ren, T.; He, B.; Shi, X. Self-Albumin Camouflage of Carrier Protein Prevents Nontarget Antibody Production for Enhanced LDL-C Immunotherapy. Adv. Healthc. Mater. 2020, 9, doi:10.1002/adhm.201901203. · DOI
  25. Crossey, E.; Amar, M.J.; Sampson, M.; Peabody, J.; Schiller, J.T.; Chackerian, B.; Remaley, A.T. A cholesterol- lowering VLP vaccine that targets PCSK9. Vaccine 2015, 33, 5747-5755, doi:10.1016/j.vaccine.2015.09.044. · DOI
  26. Pan, Y.; Zhou, Y.; Wu, H.; Chen, X.; Hu, X.; Zhang, H.; Zhou, Z.; Qiu, Z.; Liao, Y. A Therapeutic Peptide Vaccine Against PCSK9. Sci Rep 2017, 7, 12534, doi:10.1038/s41598-017-13069-w. · DOI
  27. Wu, D.; Zhou, Y.; Pan, Y.; Li, C.; Wang, Y.; Chen, F.; Chen, X.; Yang, S.; Zhou, Z.; Liao, Y.; et al. Vaccine Against PCSK9 Improved Renal Fibrosis by Regulating Fatty Acid β-Oxidation. J. Am. Heart Assoc. 2020, 9, doi:10.1161/JAHA.119.014358. · DOI
  28. Wu, D.; Pan, Y.; Yang, S.; Li, C.; Zhou, Y.; Wang, Y.; Chen, X.; Zhou, Z.; Liao, Y.; Qiu, Z. PCSK9Qβ-003 Vaccine Attenuates Atherosclerosis in Apolipoprotein E-Deficient Mice. Cardiovasc. Drugs Ther. 2020, doi:10.1007/s10557-020-07041-6. · DOI
  29. Momtazi-Borojeni, A.A.; Jaafari, M.R.; Badiee, A.; Banach, M.; Sahebkar, A. Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis. BMC Med. 2019, 17, 223, doi:10.1186/s12916-019-1457-8. · DOI
  30. Ding, Q.; Strong, A.; Patel, K.M.; Ng, S.L.; Gosis, B.S.; Regan, S.N.; Cowan, C.A.; Rader, D.J.; Musunuru, K. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ. Res. 2014, 115, 488-492, doi:10.1161/CIRCRESAHA.115.304351. · DOI · Paper page
  31. Unger, T.; Peleg, Y. Recombinant Protein Expression in the Baculovirus-Infected Insect Cell System Substrate specificity of GroEL View project Chapter 13 Recombinant Protein Expression in the Baculovirus-Infected Insect Cell System. Methods Mol. Biol. 800, doi:10.1007/978-1-61779-349-3_13. · DOI
  32. Silva Lima, B.; Videira, M.A. Toxicology and Biodistribution: The Clinical Value of Animal Biodistribution Studies. Mol. Ther. -Methods Clin. Dev. 2018, 8, 183-197.
  33. Deltcheva, E.; Chylinski, K.; Sharma, C.M.; Gonzales, K.; Chao, Y.; Pirzada, Z.A.; Eckert, M.R.; Vogel, J.; Charpentier, E. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 2011, 471, 602-607, doi:10.1038/nature09886. · DOI · Paper page
  34. Jinek, M.; Chylinski, K.; Fonfara, I.; Hauer, M.; Doudna, J.A.; Charpentier, E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science (80-. ). 2012, 337, 816-821, doi:10.1126/science.1225829. · DOI · Paper page
  35. Zalatan, J.G.; Lee, M.E.; Almeida, R.; Gilbert, L.A.; Whitehead, E.H.; La Russa, M.; Tsai, J.C.; Weissman, J.S.; Dueber, J.E.; Qi, L.S.; et al. Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds. Cell 2015, 160, 339-350, doi:10.1016/j.cell.2014.11.052. · DOI · Paper page
  36. Chadwick, A.C.; Evitt, N.H.; Lv, W.; Musunuru, K. Reduced blood lipid levels with in vivo CRISPR-Cas9 base editing of ANGPTL3. Circulation 2018, 137, 975-977.
  37. Zheng, J.; Huynh, H.D.; Umikawa, M.; Silvany, R.; Zhang, C.C. Angiopoietin-like protein 3 supports the activity of hematopoietic stem cells in the bone marrow niche. Blood 2011, 117, 470-479, doi:10.1182/blood-2010-06-291716. · DOI
  38. Chadwick, A.C.; Wang, X.; Musunuru, K. In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing. Arterioscler. Thromb. Vasc. Biol. 2017, 37, 1741-1747, doi:10.1161/ATVBAHA.117.309881. · DOI
  39. Musunuru, K.; Chadwick, A.C.; Mizoguchi, T.; Garcia, S.P.; DeNizio, J.E.; Reiss, C.W.; Wang, K.; Iyer, S.; Dutta, C.; Clendaniel, V.; et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 2021, 593, 429-434, doi:10.1038/s41586-021-03534-y. · DOI · Paper page
  40. D'Aloia, M.M.; Zizzari, I.G.; Sacchetti, B.; Pierelli, L.; Alimandi, M. CAR-T cells: The long and winding road to solid tumors review-article. Cell Death Dis. 2018, 9.
  41. Henry, S.P.; Narayanan, P.; Shen, L.; Bhanot, S.; Younis, H.S.; Burel, S.A. Assessment of the Effects of 2′- Methoxyethyl Antisense Oligonucleotides on Platelet Count in Cynomolgus Nonhuman Primates. Nucleic Acid Ther. 2017, 27, 197-208, doi:10.1089/nat.2017.0666. · DOI
  42. Flierl, U.; Nero, T.L.; Lim, B.; Arthur, J.F.; Yao, Y.; Jung, S.M.; Gitz, E.; Pollitt, A.Y.; Zaldivia, M.T.K.; Jandrot- Perrus, M.; et al. Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators. J. Exp. Med. 2015, 212, 129-137, doi:10.1084/jem.20140391. · DOI · Paper page
  43. Lundberg Slingsby, M.H.; Couldwell, G.; Vijey, P.; Terkovich, B.E.; Noetzli, L.; Okazaki, R.; Thon, J.N.; Henry, S.P.; Narayanan, P.; Italiano, J.E. Investigating Potential Mechanism(s) By Which ASO-Based Drugs Cause Thrombocytopenia. Blood 2018, 132, 3747-3747, doi:10.1182/blood-2018-99-116590. · DOI
  44. Nair, J.K.; Willoughby, J.L.S.; Chan, A.; Charisse, K.; Alam, M.R.; Wang, Q.; Hoekstra, M.; Kandasamy, P.; Kel'in, A. V.; Milstein, S.; et al. Multivalent N -Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing. J. Am. Chem. Soc. 2014, 136, 16958-16961, doi:10.1021/ja505986a. · DOI · Paper page
  45. Warden, B.A.; Duell, P.B. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins. J. Cardiovasc. Pharmacol. 2021, 78, e157-e174, doi:10.1097/FJC.0000000000001053. · DOI · Paper page
  46. Katzmann, J.L.; Packard, C.J.; Chapman, M.J.; Katzmann, I.; Laufs, U. Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias. J. Am. Coll. Cardiol. 2020, 76, 563-579, doi:10.1016/j.jacc.2020.05.070. · DOI · Paper page
  47. Springer, A.D.; Dowdy, S.F. GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics. Nucleic Acid Ther. 2018, 28, 109-118, doi:10.1089/nat.2018.0736. · DOI · Paper page
  48. Khvorova, A. Oligonucleotide Therapeutics -A New Class of Cholesterol-Lowering Drugs. N. Engl. J. Med. 2017, 376, 4-7, doi:10.1056/NEJMp1614154. · DOI
  49. Fitzgerald, K.; Frank-Kamenetsky, M.; Shulga-Morskaya, S.; Liebow, A.; Bettencourt, B.R.; Sutherland, J.E.; Hutabarat, R.M.; Clausen, V.A.; Karsten, V.; Cehelsky, J.; et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 2014, 383, 60-68, doi:10.1016/S0140-6736(13)61914-5. · DOI
  50. Levin, A.A. Targeting therapeutic oligonucleotides. N. Engl. J. Med. 2017, 376, 86-88, doi:10.1056/NEJMcibr1613559. · DOI
  51. Wright, R.S.; Collins, M.G.; Stoekenbroek, R.M.; Robson, R.; Wijngaard, P.L.J.; Landmesser, U.; Leiter, L.A.; Kastelein, J.J.P.; Ray, K.K.; Kallend, D. Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. Mayo Clin. Proc. 2020, 95, 77-89, doi:10.1016/j.mayocp.2019.08.021. · DOI
  52. Frank-Kamenetsky, M.; Grefhorst, A.; Anderson, N.N.; Racie, T.S.; Bramlage, B.; Akinc, A.; Butler, D.; Charisse, K.; Dorkin, R.; Fan, Y.; et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A 2008, 105, 11915-11920, doi:10.1073/pnas.0805434105. · DOI
  53. Banerjee, Y.; Pantea Stoian, A.; Cicero, A.F.G.; Fogacci, F.; Nikolic, D.; Sachinidis, A.; Rizvi, A.A.; Janez, A.; Rizzo, M. Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. Expert Opin. Drug Saf. 2021, doi:10.1080/14740338.2022.1988568. · DOI · Paper page
  54. Ray, K.K.; Corral, P.; Morales, E.; Nicholls, S.J. Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. Lancet 2019, 394, 697-708.
  55. Landmesser, U.; Haghikia, A.; Leiter, L.A.; Wright, R.S.; Kallend, D.; Wijngaard, P.; Stoekenbroek, R.; Kastelein, J.J.; Ray, K.K. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1. Cardiovasc. Res. 2020, doi:10.1093/cvr/cvaa077. · DOI · Paper page
  56. Ray, K.K.; Landmesser, U.; Leiter, L.A.; Kallend, D.; Dufour, R.; Karakas, M.; Hall, T.; Troquay, R.P.; Turner, T.; Visseren, F.L.; et al. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. N Engl J Med 2017, 376, 1430-1440, doi:10.1056/NEJMoa1615758. · DOI · Paper page
  57. Chi, X.; Gatti, P.; Papoian, T. Safety of antisense oligonucleotide and siRNA-based therapeutics. Drug Discov. Today 2017, 22, 823-833.
  58. Dolgin, E. Lp(a)-lowering drugs bolster cardiovascular pipeline. Nat. Rev. Drug Discov. 2020, 19, 154-155.
  59. Merki, E.; Graham, M.; Taleb, A.; Leibundgut, G.; Yang, X.; Miller, E.R.; Fu, W.; Mullick, A.E.; Lee, R.; Willeit, P.; et al. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J. Am. Coll. Cardiol. 2011, 57, 1611-1621, doi:10.1016/j.jacc.2010.10.052. · DOI · Paper page
  60. Yu, R.Z.; Grundy, J.S.; Geary, R.S. Clinical pharmacokinetics of second generation antisense oligonucleotides. Expert Opin. Drug Metab. Toxicol. 2013, 9, 169-182.
  61. Loscalzo, J.; Weinfeld, M.; Fless, G.M.; Scanu, A.M. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990, 10, 240-245, doi:10.1161/01.atv.10.2.240. · DOI
  62. Rouy, D.; Grailhe, P.; Nigon, F.; Chapman, J.; Angles-Cano, E. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator: In vitro studies in a plasma milieu. In Proceedings of the Arteriosclerosis and Thrombosis; Arterioscler Thromb, 1991; Vol. 11, pp. 629-638.
  63. Palabrica, T.M.; Liu, A.C.; Aronovitz, M.J.; Furie, B.; Lawn, R.M.; Furie, B.C. Antifibrinolytic activity of apolipoprotein(a) in vivo: Human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator- mediated thrombolysis. Nat. Med. 1995, 1, 256-259, doi:10.1038/nm0395-256. · DOI
  64. Biemond, B.J.; Friederich, P.W.; Koschinsky, M.L.; Levi, M.; Sangrar, W.; Xia, J.; Büller, H.R.; Ten Cate, J.W. Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo. Circulation 1997, 96, 1612-1615, doi:10.1161/01.CIR.96.5.1612. · DOI
  65. Boffa, M.B.; Marar, T.T.; Yeang, C.; Viney, N.J.; Xia, S.; Witztum, J.L.; Koschinsky, M.L.; Tsimikas, S. Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis. J. Lipid Res. 2019, 60, 2082-2089, doi:10.1194/jlr.P094763. · DOI
  66. Helgadottir, A.; Gretarsdottir, S.; Thorleifsson, G.; Holm, H.; Patel, R.S.; Gudnason, T.; Jones, G.T.; Van Rij, A.M.; Eapen, D.J.; Baas, A.F.; et al. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J. Am. Coll. Cardiol. 2012, 60, 722- 729, doi:10.1016/j.jacc.2012.01.078. · DOI
  67. Kamstrup, P.R.; Tybjærg-Hansen, A.; Nordestgaard, B.G. Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis. Arterioscler. Thromb. Vasc. Biol. 2012, 32, 1732-1741, doi:10.1161/ATVBAHA.112.248765. · DOI
  68. Boffa, M.B.; Koschinsky, M.L. Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. Nat. Rev. Cardiol. 2019, 16, 305-318.
  69. Adam, R.C.; Mintah, I.J.; Alexa-Braun, C.A.; Shihanian, L.M.; Lee, J.S.; Banerjee, P.; Hamon, S.C.; Kim, H.I.; Cohen, J.C.; Hobbs, H.H.; et al. Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. J. Lipid Res. 2020, 61, 1271-1286, doi:10.1194/jlr.RA120000888. · DOI · Paper page
  70. Wu, L.; Soundarapandian, M.M.; Castoreno, A.B.; Millar, J.S.; Rader, D.J. LDL-Cholesterol Reduction by ANGPTL3 Inhibition in Mice Is Dependent on Endothelial Lipase. Circ. Res. 2020, 127, 1112-1114, doi:10.1161/CIRCRESAHA.120.317128. · DOI
  71. Alexander, V.J.; Xia, S.; Hurh, E.; Hughes, S.G.; O'Dea, L.; Geary, R.S.; Witztum, J.L.; Tsimikas, S. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. Eur. Heart J. 2019, 40, 2785-2796, doi:10.1093/eurheartj/ehz209. · DOI · Paper page
  72. Post, N.; Yu, R.; Greenlee, S.; Gaus, H.; Hurh, E.; Matson, J.; Wang, Y. Metabolism and disposition of volanesorsen, a 29-O-(2 methoxyethyl) antisense oligonucleotide, across species. Drug Metab. Dispos. 2019, 47, 1164-1173, doi:10.1124/dmd.119.087395. · DOI
  73. Alexander, V.J.; Digenio, A.; Xia, S.; Hurh, E.; Hughes, S.; Geary, R.S.; Witztum, J.L.; Tsimikas, S. Inhibition pf apolipoprotein CIII with GalNac conjugated antisense drug potently lowers fasting serum apolipoprotein CIII and triglycerides levels in healthy volunteers with elevated triglycerides. JACC 2018, 71, (abstract) doi:10.1016/S0735- 1097. · DOI

Cited by

Sorted by citations

Authors
Bellosta, S., Rossi, C., Alieva, A. S., Catapano, A. L., Corsini, A., & Baragetti, A.
Affiliations
University of Milan (IT)
Corresponding author
Corsini, A.
ORCID
Venue
Cardiovascular Drugs and Therapy
Publisher
Springer Science and Business Media LLC
Published
2022-01-13
Volume
37
Issue
3
Pages
585-598
ISSN
  • 0920-3206 (ISSN-L)
  • 1573-7241
DOI
10.1007/s10557-021-07293-w
OpenAlex
W4205899727
Cited by
10
References
11
Citations by year
2026: 2 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 4
FWCI
0.48
Type
journal article
Language
en
Open access
Licence
Locations
  • Cardiovascular Drugs and Therapy (publishedVersion)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
Funders
  • Amgen
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • Sanofi
  • Teva Pharmaceutical Industries
  • Regeneron Pharmaceuticals
  • Kowa Company
  • Fondazione Cariplo (2015-0524, H2020 REPROGRAM PHC-03-2015/667837-2, GR-2011-02346974, 2015-0564, ER-2017-2364981, 2017H5F943, AL_RIC19ABARA_01, H2020 REPROGRAM, PHC-03-2015/667837-2)
  • Daiichi-Sankyo
  • Ministero della Salute (PRIN 2017H5F943, GR‐2011‐02346974, ER-2017-2364981)
  • Fondazione Umberto Veronesi (“Post-Doctoral Fellowship 2020”, Fellowship 2020, 2020‐3318)
  • Servier
  • Horizon 2020 Framework Programme (GR-2011-02346974, REPROGRAM PHC-03-2015/667837-2, 667837, PHC-03-2015/667837–2)
  • Daiichi Sankyo Europe
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
cholesterol lowering, dyslipidemia, monoclonal antibodies, antisense oligonucleotides, siRNA, gene therapy, familial hypertriglyceridemia, hyperchylomicronemia, preclinical drug development, cardiovascular therapeutics
MeSH terms
Proprotein Convertase 9, Antibodies, Monoclonal, Anticholesteremic Agents, Cholesterol, Cholesterol, LDL, Oligonucleotides, Antisense

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review